Self-Replicating RNA Constructs for IL-12 and IL-1RA Expression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for delivering IL-12 and IL-1RA face challenges such as dose-limiting toxicity and stability issues, limiting their clinical effectiveness in treating cancers and infections.
Innovation Solution
Development of nucleic acid constructs encoding modified alphavirus genomes or self-replicating RNA (srRNA) that express p35 subunit of IL-12, p40 subunit of IL-12, and IL-1RA, along with recombinant cells and pharmaceutical compositions for enhanced immunotherapy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If systemic administration of IL-12 is used to treat tumors, then anti-tumor activity is improved, but dose-limiting toxicity occurs
Solution Approach 1:
The patent divides the therapeutic approach into two distinct components: IL-12 for anti-tumor activity and IL-1RA for toxicity management. These are delivered separately but work synergistically, allowing the therapeutic benefits of IL-12 while mitigating its harmful effects through concurrent IL-1RA administration
Solution Approach 2:
IL-1RA acts as an intermediary that modulates the immune response to IL-12 therapy. By blocking IL-1 signaling pathways that contribute to toxicity, IL-1RA mediates protection against harmful effects while permitting IL-12 to maintain its anti-tumor efficacy
2Reliability
If recombinant IL-12 is administered to achieve therapeutic effects, then anti-tumor activity is improved, but stability and half-life issues limit clinical effectiveness
Solution Approach 1:
The patent employs preliminary action by using viral vectors (adenovirus, aden-associated virus, or vaccinia virus) to deliver IL-12 genes directly to target cells. This establishes sustained endogenous production of IL-12 at the site of action, overcoming the short half-life limitation of recombinant protein administration
Solution Approach 2:
The viral vector system enables self-service by allowing the body's own cellular machinery to continuously produce IL-12 from the delivered genes. This creates a localized, sustained source of the cytokine that automatically maintains therapeutic levels without requiring repeated external administrations
3Ease of operation
If current delivery methods are used for IL-12 and IL-1RA, then therapeutic administration is achieved, but dose-limiting toxicity and stability issues limit clinical effectiveness
Solution Approach 1:
The patent merges two previously separate therapeutic approaches (IL-12 and IL-1RA) into a coordinated treatment regimen. By combining these agents with different mechanisms of action, the therapy achieves synergistic effects that improve clinical effectiveness while managing toxicity through the complementary actions of the two components
Data Source
AI summary
The present disclosure relates to the field of molecular virology, and particularly relates to nucleic acid molecules encoding a modified alphavirus virus viral genome or self-replicating RNA (srRNA) construct, pharmaceutical compositions containing the same, and the use of such nucleic acid molecules and compositions for production of desired products in cell cultures or in a living body. Also provided are methods for eliciting a pharmacodynamics effect in a subject.